Across TCGA pan-cancer cohorts, BCL9L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCL9L data layer compared with 30 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BCL9L mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BCL9L expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where BCL9L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.829	0.463	.001	39	view →
HNSC	DFS	Median	III,IV	0.818	0.262	.012	11	view →
CCRCC	OS	Median	All	0.906	1.000	.016	6	view →
PDAC	OS	Quartile	III,IV	0.566	0.977	.027	6	view →
LSCC	OS	Tertile	II,III,IV	0.766	0.930	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: BCL9L tumor-vs-normal RNA expression · all BCL9L data types